Effects of Plasma-Derived C1 Inhibitor Concentrate on Risk of Thromboembolism in Patients with Hereditary Angioedema Due to C1-Inhibitor Deficiency

Trial Profile

Effects of Plasma-Derived C1 Inhibitor Concentrate on Risk of Thromboembolism in Patients with Hereditary Angioedema Due to C1-Inhibitor Deficiency

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top